Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
--No other concerns stated, including pre-clinical, clinical, or safety data
--The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Manufacturing and Controls (CMC) issues identified in the CRL
--The Company plans to immediately request a Type A meeting with the FDA to align on next steps
--Unicycive currently has an unaudited cash balance of approximately $20.7 million, with cash runway currently expected into the second half of 2026
LOS ALTOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ('Unicycive' or the 'Company') (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has issued a CRL for its New Drug Application (NDA) for OLC to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
'We plan to immediately seek a Type A meeting with the Agency to gain alignment on the best strategy to ensure rapid resolution of the CRL,' said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. 'With a second manufacturing vendor identified that has produced OLC drug product, we remain optimistic about our ability to bring this promising new treatment option to patients with CKD on dialysis who are managing hyperphosphatemia, and we plan to provide an update as soon as we have additional clarity on next steps from the FDA.'
After submitting the NDA, and as a part of the application review and routine information requests, the FDA notified Unicycive that a third-party manufacturing vendor of its main contract development and manufacturing organization (CDMO) was cited for deficiencies following a cGMP inspection. This citation is unrelated to OLC. Unicycive also notes that as part of the NDA review, the Agency has not highlighted any other technical concerns related to the submitted CMC documentation or testing of OLC itself.
As part of its overall manufacturing strategy, the Company had previously identified a back-up third-party manufacturing vendor to build redundancy into its supply chain. The second vendor has a long history of successful FDA and international regulatory inspections and has already produced OLC drug product, which could also be used to support the resolution of the CMC issues identified in the CRL.
About Oxylanthanum Carbonate (OLC)
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as 'anticipate,' 'believe,' 'forecast,' 'estimated' and 'intend' or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. Epub 2023 Jun 29. PMID: 37229723; PMCID: PMC10371371.
Investor Contact:
Kevin Gardner
LifeSci Advisors
[email protected]
Media Contact:
Rachel Visi
Real Chemistry
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Hungry for Yield? How You Should Play This Famous Dividend Aristocrat Stock Now.
World-leading fast-food chain McDonald's (MCD) reported a second-quarter earnings victory that helped alleviate investor concerns about the strength of the brand in a tough environment for consumers. With the help of promotional crossovers, new menu items, and worldwide demand, the Golden Arches notched its biggest same-store sales increase in close to two years. Its shares climbed over 2% in early trading on the back of the Street's positive response to the figures. Nevertheless, executives took a cautious line on U.S. low-income consumer trends, where traffic continues under pressure. With inflation-fatigued consumers cutting back on expenditure, McDonald's is relying on value-driven promotions and global expansion to keep the pedal to the floor. The figures come as the overall quick-service restaurant segment fights for share of the market with slowing traffic and changing expenditure trends. More News from Barchart UnitedHealth Stock Soars as Warren Buffett's Berkshire Hathaway Discloses $1.57B Stake Palantir CEO Alex Karp Sees More Gains Ahead With America-Focused Growth Strategy, Calls U.S. The 'Leader of the Free World' Lucid Motors Is Caught in a Tariff Trap. Is LCID Stock More Likely to Hit $1 or $7 in 2025? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About McDonald's Stock McDonald's has a market cap of $218 billion and has over 40,000 restaurants and franchise locations globally, with about 69 million daily customers. Based in Chicago, Illinois, the $219 billion company dominates the world's quick service restaurant sector with a combination of company-owned restaurants and a massive franchise network in over 100 countries worldwide. Over the past 52 weeks, MCD shares have traded between $271.85 and $326.32, recently changing hands at $304.89, modestly above their yearly lows and trailing the S&P 500's ($SPX) roughly 25% gain over the same period. Its stock has a forward price-earnings (P/E) ratio of 24.72, slightly higher than the restaurant chain average, in line with investor optimism about the pricing power and brand sustainability of the company. The price-sales (P/S) ratio of 8.40 and the price-cash flow ratio (P/CF) of 20.71 indicate a premium multiple, but steady free cash flow (FCF) and resilient margins support the multiple. With over four decades of annual dividend increases, McDonald's is a Dividend Aristocrat, and the stock provides a payout of to 2.29%, with quarterly payments underpinned by a 31.73% profit margin and healthy cash generation. The next dividend payout will come in September. McDonald's Beats on Earnings In Q2 2025, McDonald's reported adjusted EPS of $3.19, beating the $3.15 consensus estimate, and revenue of $6.84 billion, topping the $6.7 billion forecast. Net income rose 11% year-over-year to $2.25 billion, driven by a 3.8% global same-store sales increase, the largest in nearly two years. U.S. comparable sales rose 2.5%, reversing two straight quarters of declines, supported by promotions like the $5 meal deal, the Minecraft movie tie-in, and the launch of McCrispy Chicken Strips. Management expects stronger results in the second half of 2025, citing easier year-over-year comparisons and continued international momentum. International Operated Markets posted 4% same-store sales growth, while International Developmental Licensed Markets surged 5.6%, led by Japan, China, and the UK. Soon after the quarter closed, the comeback of Snack Wraps to a $2.99 promotional pricing level met with 'encouraging' initial response, with franchisees opting for the year-end continuation of the offer. Company executives also highlighted the company's loyalty program, which generated $9 billion in quarterly system-wide sales by members. What Do Analysts Expect for McDonald's Stock? Barchart data shows that MCD stock has a 'Moderate Buy' rating consensus based on the strength of the brand, scale benefits, and pricing opportunities as the primary long-term strengths. Though some analysts have reduced near-term expectations in response to U.S. traffic headwinds, the overall sentiment remains positive. Its average target of $337.43 offers about 10.7% potential upside from the recent close. The top target of $373 offers upside potential of approximately 22%, and the bottom target of $260 indicates possible downside risk of roughly 14.7%. Analysts' primary catalysts for ongoing earnings growth and shareholder returns include international expansion, menu innovation, and digital engagement. On the date of publication, Yiannis Zourmpanos did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
24 minutes ago
- Yahoo
Busy September US corporate bond market expected despite lower rate cut odds
By Matt Tracy and Shankar Ramakrishnan (Reuters) -Companies' U.S. dollar bond issuance will likely carry September to one of the heaviest months for investment-grade supply this year, despite more volatility in Treasury yields as hopes for a bigger Federal Reserve interest rate cut were dimmed by recent data that pointed to still-sticky inflation, said bankers and strategists. September has historically averaged roughly $140 billion of investment-grade bond issuance, according to data from Informa Global Markets. But last year set a record for the busiest September with over $172 billion in new deals, as companies rushed to seize on healthy investor appetite for higher yields, according to the IGM data. The latest inflation data this week showed U.S. producer prices surged while consumer prices rose in line with forecasts, in turn leading the market to place lower odds on a substantial interest rate cut from the Federal Reserve next month. But bond bankers expect this September could again tally robust corporate bond volumes despite the high inflation print and a change in the Fed's expected rate-cutting path, as corporate treasurers are not expected to let this sway their planned issuance. "Data pointing to some delay in interest rate cuts probably does not influence corporate bond issuance in September," said Victor Forte, head of IG capital markets and U.S. debt syndicate at New York City-based investment bank Mizuho Americas. "It is traditionally a busy month and is expected to be so again regardless of small changes in spreads (or) yields,' Forte added. Corporate credit spreads, or the premium over Treasuries paid by companies, widened a few basis points on some corporate bonds this week, but they have not moved materially enough to shift company treasurers' September bond issuance plans next month, Forte said. 'Their decision to issue bonds in September hinges more on corporate finance needs than it is trying to predict when the Fed may cut interest rates," he said. Corporate spreads on average moved about 1 bp tighter this week and were last at 77 bps, making them just 3 bps closer to their tightest levels since reaching 74 bps on July 28, 1998, according to ICE BAML index. Bond yields were at 4.94% or 41 bps inside levels they touched in January, the same index data showed. Bond bankers and analysts similarly expect a busy August for IG bond issuance heading into the expected high September volume, even with an expected quiet period in the two weeks before Labor Day. "With expectations for annual IG supply wrapped around $1.5 trillion in future years, you can expect busier calendars as we approach end of summer going forward,' said Kyle Stegemeyer, head of IG debt capital markets and syndicate at Minneapolis-based U.S. Bank. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
FACT FOCUS: No, taxpayers will not receive new stimulus checks this summer
Don't splurge just yet. Rumors spread online Friday that the U.S. government will soon be issuing stimulus checks to taxpayers in certain income brackets. But Congress has not passed legislation to authorize such payments, and, according to the IRS, no new stimulus checks will be distributed in the coming weeks. Here's a closer look at the facts. CLAIM: The Internal Revenue Service and the Treasury Department have approved $1,390 stimulus checks that will be distributed to low- and middle-income taxpayers by the end of the summer. THE FACTS: This is false. Taxpayers will not receive new stimulus checks of any amount this summer, an IRS official said. Stimulus checks, also known as economic impact payments, are authorized by Congress through legislation and distributed by the Treasury Department. Republican Sen. Josh Hawley of Missouri last month introduced a bill that would send tax rebates to qualified taxpayers using revenue from tariffs instituted by President Donald Trump. Hawley's bill has not passed the Senate or the House. The IRS announced early this year that it would distribute about $2.4 billion to taxpayers who failed to claim on their 2021 tax returns a Recovery Rebate Credit — a refundable credit for individuals who did not receive one or more COVID-19 stimulus checks. The maximum amount was $1,400 per individual. Those who hadn't already filed their 2021 tax return would have needed to file it by April 15 to claim the credit. The IRS official said there is no new credit that taxpayers can claim. Past stimulus checks have been authorized through legislation passed by Congress. For example, payments during the coronavirus pandemic were made by possible by three bills: the Coronavirus Aid, Relief and Economic Security Act; the COVID-related Tax Relief Act; and the American Rescue Plan Act. In 2008, stimulus checks were authorized in response to the Great Recession through the Economic Stimulus Act. The Treasury Department, which includes the Internal Revenue Service, distributed stimulus payments during the COVID-19 pandemic and the Great Recession. The Treasury's Bureau of the Fiscal Service, formed in 2012, played a role as well during the former crisis. Hawley in July introduced the American Worker Rebate Act, which would share tariff revenue with qualified Americans through tax rebates. The proposed rebates would amount to at minimum $600 per individual, with additional payments for qualifying children. Rebates could increase if tariff revenue is higher than expected. Taxpayers with an adjusted annual gross income above a certain amount — $75,000 for those filing individually — would receive a reduced rebate. Hawley said Americans 'deserve a tax rebate.' 'Like President Trump proposed, my legislation would allow hard-working Americans to benefit from the wealth that Trump's tariffs are returning to this country,' Hawley said in a press release. Neither the Senate nor the House had passed the American Worker Rebate Act as of Friday. It was read twice by the Senate on July 28, the day it was introduced, and referred to the Committee on Finance. ___ Find AP Fact Checks here: Melissa Goldin, The Associated Press
